Wednesday, June 22, 2011

Robotic One-Port Gallbladder Surgery Feasible



By John Gever, Senior Editor, MedPage Today
June 21, 2011




MedPage Today Action Points


•Explain that outcomes were just as good with robotic single-port cholecystectomy as with conventional laparoscopic procedures in a pilot study of 10 patients.




•Note that mean operating room time was nearly identical with the robotic procedure and conventional multiport laparoscopy.




Review
Outcomes were just as good with robotic single-port cholecystectomy as with conventional laparoscopic procedures in a pilot study, researchers said.


The robotic surgery was attempted in 10 patients and completed in nine, with the same average operating room time as in 10 standard laparascopic gallbladder removals, according to Sherry Wren, MD, and Myriam Curet, MD, of Stanford University and the Palo Alto VA Health Care System.


No serious adverse events were seen after the robotic procedures, the first such single-port surgeries conducted with Intuitive Surgical's da Vinci Si system, the researchers wrote online in Archives of Surgery.


Both physicians were affiliated with Intuitive Surgical -- Wren as a consultant and Curet as chief medical advisor.


In their Archives report, they explained that single-port laparascopic surgery has attracted interest in recent years because of the possibility of reduced pain, faster recovery, and less scarring.


They cited a recent review that counted more than 4,500 patients having received single-port procedures for a variety of purposes.


But, Wren and Curet noted, "there has not been a large clinical trial comparing [single-port] surgery versus standard multiport laparoscopy, so the clinical benefits of this new technique are purely speculative.


They did not have the resources to conduct such a study themselves, but they were able to compare outcomes in the first 10 cholecystecomies they attempted with the da Vinci Si system with the last 10 multiport laparoscopic procedures Wren had performed at the Palo Alto VA hospital.


Seven of the patients undergoing single-port surgery were male and were otherwise representative of the usual VA population, Wren and Curet indicated.


The one single-port procedure that could not be completed involved a patient with significant adhesions of the omentum to the diaphragm, such that it was necessary to use, first, multiport laparoscopy and then open surgery to finally remove the diseased organ, the researchers explained. That patient was not included in the analysis of procedure time.


Among the nine patients with completed single-port surgeries, the mean operating room time was 105 minutes (SD 18), compared with 106 minutes (SD 24) for the control group. "There did not appear to be a significant learning curve for the [single-port] procedure," Wren and Curet wrote.


The presence of inflammation, seen in six of the nine patients included in the analysis, tended to prolong the procedure. Operating room time for the patients without inflammation was 82 to 88 minutes, whereas in two patients with empyema and hydrops the procedures took two hours or more.


The surgeon spent an average of just over one hour (range 38 to 99 minutes) at the operative console during the procedure.


Other tasks adding to operating room time included preparing the port (mean 17 minutes from skin incision to cannula insertion), docking the robotic arms (mean 5 minutes), and port removal and closure (mean 18 minutes).


No intraoperative complications were reported, and with follow-up ranging from five to 10 months, Wren and Curet saw no serious adverse events.


Two male patients had postoperative urinary retention requiring a urinary catheter during the first night. One was discharged with a catheter, which was removed a week later.


One patient in the control group developed atrial fibrillation, and two male patients had urinary retention, the researchers reported.


During the first few robotic procedures, there were two cases in which part of the access port device tore off as the specimen extraction bag was placed and the pieces needed to be retrieved. Wren and Curet indicated that they then revised their technique for inserting the specimen bag and the problem did not recur.


On a standard 10-point scale, patients rated pain at discharge with a mean score of 2.5. The mean score at a postoperative visit two to three weeks later was 0.67.


Asked their opinions 30 days after surgery, the robotic surgery patients told the researchers they were highly satisfied with the robotic surgery and would recommend it to others.


"The da Vinci single-site platform performed equivalently to traditional multiport cholecystectomy in this human use study," Wren and Curet wrote.


However, they noted, "additional trials would need to be performed to directly compare it with current single-port surgery."


The study had no external funding. Intuitive Surgical provided the instrumentation used in the study.


Wren reported serving as a consultant to Intuitive Surgical.


Curet reported serving as the company's chief medical advisor.


Primary source: Archives of Surgery
Source reference:
Wren S, et al "Single-port robotic cholecystectomy: results from a first human use clinical study of the new da Vinci single-site surgical platform" Arch Surg 2011; DOI: 10.1001/archsurg.2011.143.


--------------------------------------------------------------------------------
Disclaimer
The information presented in this activity is that of the authors and does not necessarily represent the views of the University of Pennsylvania School of Medicine, MedPage Today, and the commercial supporter. Specific medicines discussed in this activity may not yet be approved by the FDA for the use as indicated by the writer or reviewer. Before prescribing any medication, we advise you to review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects. Specific patient care decisions are the responsibility of the healthcare professional caring for the patient. Please review our Terms of Use.


© 2004-2011 MedPage Today, LLC. All Rights Reserved.

Saturday, June 18, 2011

The inpatient burden of abdominal and gynecological adhesiolysis in the US


Adhesions are fibrous bands of scar tissue, often a result of surgery, that form between internal organs and tissues, joining them together abnormally. Postoperative adhesions frequently occur following abdominal surgery, and are associated with a large economic burden.

This study examines the inpatient burden of adhesiolysis in the United States (i.e ., number and rate of events, cost, length of stay [LOS]).

Methods: Hospital discharge data for patients with primary and secondary adhesiolysis were analyzed using the 2005 Healthcare Cost and Utilization Project's Nationwide Inpatient Sample. Procedures were aggregated by body system.

Results: We identified 351,777 adhesiolysis-related hospitalizations: 23.2% for primary and 76.8% for secondary adhesiolysis.

The average LOS was 7.8 days for primary adhesiolysis. We found that 967,332 days of care were attributed to adhesiolysis-related procedures, with inpatient expenditures totaling $2.3 billion ($1.4 billion for primary adhesiolysis; $926 million for secondary adhesiolysis).

Hospitalizations for adhesiolysis increased steadily by age and were higher for women. Of secondary adhesiolysis procedures, 46.3% involved the female reproductive tract, resulting in 57,005 additional days of care and $220 million in attributable costs.

Conclusions: Adhesiolysis remain an important surgical problem in the United States.

Hospitalization for this condition leads to high direct surgical costs, which should be of interest to providers and payers.

Author: Vanja SikiricaBela BapatSean CandrilliKeith DavisMalcolm WilsonAlan Johns
Credits/Source: BMC Surgery 2011, 11:13

Wednesday, June 15, 2011

FDA Risk of Air or Gas Embolism When Using Air- or Gas- Pressurized Spray Devices

Ummm do you mean like Sprayshield too???????Does Kruschinski know about this...another way to maim his poor patients. Is Carl aware of this too? I'm betting he does not!

FDA Safety Notification: Risk of Air or Gas Embolism When Using Air- or Gas- Pressurized Spray Devices
Date Issued: July 9, 2010


Audience: Surgeons, Operating Room Nurses, and other support personnel in the Operating Room


Products:
Air- or gas-pressurized sprayers are dual syringe products that simultaneously mix and apply two non-homogeneous liquids within a single spray head that is connected to a pressure regulator and a source of compressed air or gas. Air- or gas-pressurized sprayers can be used to mix and apply hemostatic drug or biological products (products that help control bleeding from blood vessels during surgery) including fibrin and non-fibrin sealants.


They include devices such as:


EasySpray and spray set used with Duploject system(Baxter Healthcare Corporation)
Tissomat and spray set used with Duploject system (Baxter Healthcare Corporation)
Evicel application device (Omrix Medical)
FibriJet Aerosol Applicator (MicroMedics)
HemaMyst Surgical Applicator System (Heamacuare Corporation)
MicroMyst Applicator and Air Pump Models 20-5000 and AP-A-6063 (Confluent Surgical)
Vitagel Hemostat Spray Set (Orthovita, Inc.)
Summary of Problem and Scope:
FDA has received reports of air or gas embolisms occurring during or immediately after application of hemostatic drug or biological products using air- or gas- pressurized sprayers. Although rare, the reports describe air embolisms that are life threatening and include one fatality.


These adverse events appear to be related to use of spray devices inconsistent with the approved product labeling and instructions for use. In some reports the device was used at higher than recommended pressure or at a distance too close to the surface of the bleeding site.


Recommendations/Actions:
Given the life-threatening consequences of an air or gas embolism, FDA is recommending that clinicians using air- or gas- pressurized spray devices for application of hemostatic drug or biological products:


Use the applicator, spray set, and pressure control device or regulator as recommended in the labeling or Information For Use (IFU) of the hemostatic agent.
Use an air or gas pressure setting within the range recommended by the manufacturer of the sprayer.
Ensure that distance between the spray head and the tissue surface is not less than the minimum recommended by the manufacturer of the sprayer.
Monitor blood pressure, pulse, oxygen saturation and end tidal CO 2 for signs of an air or gas embolism.
Make sure the regulators are maintained properly and checked for safe performance regularly.
FDA Activities:
In cooperation with the FDA, Baxter Healthcare Corporation and Omrix Pharmaceuticals, the manufacturers of all fibrin sealants licensed in the U.S., have updated the Warning and Precautions sections of the labels of EVICEL, T isseel and ARTISS to emphasize the risk of air embolism and the need to use the recommended ranges of pressure and distance.


The labeling of the spray devices and non-fibrin hemostatic drug or biological products also includes information on recommended pressures and distances.


Report Problems to FDA:
Prompt reporting of adverse events can help FDA identify and better understand the risks associated with medical products. If you suspect problems with the use of fibrin sealants and/or air or gas pressurized fibrin sprayers, we encourage you to file a voluntary report through MedWatch, the FDA Safety Information and Adverse Event Reporting program1. Healthcare personnel employed by facilities that are subject to FDA's device user facility reporting requirements2 should follow the reporting procedures established by their facilities.


Contact Information:
If you have questions about this communication, please contact the Division of Small Manufacturers, International and Consumer Assistance (DSMICA) at DSMICA@FDA.HHS.GOV or 800-638-2041.
http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm218523.htm

Ceftriaxone Injection

Ceftriaxone Injection(sef try ax' one)
Last Revision: March 16, 2011.


Why is this medication prescribed?
Ceftriaxone injection is used to treat certain infections caused by bacteria such as gonorrhea (a sexually transmitted disease), pelvic inflammatory disease (infection of the female reproductive organs that may cause infertility), meningitis (infection of the membranes that surround the brain and spinal cord), and infections of the lungs, ears, skin, urinary tract, blood, bones, joints, and abdomen. Ceftriaxone injection is also sometimes given before certain types of surgery to prevent infections that may develop after the operation. Ceftriaxone injection is in a class of medications called cephalosporin antibiotics. It works by killing bacteria. Antibiotics will not work for colds, flu, or other viral infections.


How should this medicine be used?
Ceftriaxone injection comes as a liquid to be injected intravenously (into a vein) or intramuscularly (into a muscle). It is sometimes given as a single dose and sometimes given once or twice a day for 4-14 days, depending on the type of infection being treated. You may receive ceftriaxone injection in a hospital or doctor's office, or you may administer the medication at home. If you are using ceftriaxone injection at home, use it at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use ceftriaxone injection exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.


You should begin to feel better during the first few days of your treatment with ceftriaxone injection. If your symptoms do not improve or get worse, call your doctor.


If you will be using more than one dose of ceftriaxone injection, use the medication until you finish the prescription, even if you feel better. If you stop using ceftriaxone injection too soon or skip doses, your infection may not be completely treated and the bacteria may become resistant to antibiotics.


Other uses for this medicine
Ceftriaxone injection is also sometimes used to treat endocarditis (infection of the heart lining and valves), chancroid (genital sores caused by bacteria), Lyme disease (an infection that is transmitted by tick bites that may cause problems with the heart, joints, and nervous system), relapsing fever (an infection that is transmitted by tick bites that causes repeated episodes of fever), shigella (an infection that causes severe diarrhea), typhoid fever (a serious infection that is common in developing countries), salmonella (an infection that causes severe diarrhea), and Whipple's disease (a rare infection that causes serious problems with digestion). Ceftriaxone injection is also sometimes used to prevent infection in people who have been sexually assaulted or who have been bitten by humans or animals. Talk to your doctor about the risks of using this medication for your condition.


This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.


What special precautions should I follow?
Before using ceftriaxone injection,


•tell your doctor and pharmacist if you are allergic to ceftriaxone injection, other cephalosporin or penicillin antibiotics, or any other medications.


•tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any intravenous medications or feedings that contain calcium such as total parenteral nutrition (TPN, a liquid feeding that is given intravenously to people who cannot eat or digest food).


•tell your doctor if you have or have ever had problems with your digestive system, especially colitis (inflammation of the large intestine), malnutrition (you do not eat or cannot digest the nutrients needed for good health), or kidney or liver disease.


•tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while using ceftriaxone injection, call your doctor.


What special dietary instructions should I follow?
Unless your doctor tells you otherwise, continue your normal diet.


What should I do if I forget a dose?
Use the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not use a double dose to make up for a missed one.


What side effects can this medication cause?
Ceftriaxone injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:


pain, tenderness, hardness, or warmth in the place where ceftriaxone was injected


headache


dizziness


sweating


flushing


diarrhea




Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately:


rash


bloody, watery stools


fever


stomach cramps


stomach pain or bloating


nausea and vomiting


heartburn


chest pain




Ceftriaxone injection may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.


What storage conditions are needed for this medicine?
If you will be injecting ceftriaxone injection at home, your health care provider will tell you where you should store it and how long you may keep it. Follow these directions carefully. Be sure to store ceftriaxone in the container it came in and out of reach of children. Throw away any medication that is outdated or no longer needed. Talk to your health care provider about the proper disposal of your medication.


In case of emergency/overdose
In case of overdose, call your local poison control center at 1-800-222-1222. If the victim has collapsed or is not breathing, call local emergency services at 911.


What other information should I know?
Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check your body's response to ceftriaxone.


Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.


It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.




American Society of Health-System Pharmacists, Disclaimer


AHFS® Consumer Medication Information. © Copyright, 2011. The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.


The following brand names are from RxNorm, a standardized nomenclature for clinical drugs produced by the National Library of Medicine:
Brand names
•Rocephin

Friday, June 03, 2011

Adhesiolysis in Repeat Caesarean Delivery Common, Costly


Medscape Medical News from the:

American Congress of Obstetricians and Gynecologists (ACOG) 59th Annual Clinical Meeting




May 20, 2011 (Washington, DC) — Adhesions from previous Caesarean deliveries severe enough to require adhesiolysis during repeat Caesarean delivery have clinical and economic implications, according to a retrospective review of a large database with discharge data from 60 hospitals in the United States. The data were reported here at the American Congress of Obstetricians and Gynecologists 59th Annual Clinical Meeting.


The matched cohort study found that for patients who required adhesiolysis, the cost per patient was $300 more, operative length was longer, hospital stay was longer, and postoperative complications were more frequent.
Read the rest: http://www.medscape.com/viewarticle/743097